Tariffs | pharmaphorum

Friday 5 December 2025

Tariffs

News

Hikma promotional picture

Generic drugmaker Hikma pledges $1bn in US investment

With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.

Market Access

American flag waving with the Capitol Hill

Four months, 157 Executive Orders: Inside the science of Tru...

When Donald Trump returned to the White House in January 2025, the question wasn't whether his administration would change the direction of US health policy – it was how quickly, how deeply

R&D

medtech supply chain concept

Tariff turbulence: Navigating US trade shifts in the medtech...

The US has been at the centre of a shift in global trade dynamics these last few weeks, resulting from a rise in geopolitical and economic uncertainty.

News

Sanofi pledges a $20 billion investment programme in the US

Sanofi pledges a $20 billion investment programme in the US

Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US.

News

Pharma still in waiting mode after UK-US trade agreement

Pharma still in waiting mode after UK-US trade agreement

Hopes that the UK-US trade agreement would give some clarity on the situation for pharmaceuticals proved optimistic.

News

Gilead Sciences' chief executive Daniel O'Day

Gilead ups its US investment plans by $11 billion

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.